|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 133.20 SEK | +4.72% |
|
+1.99% | +3.90% |
| 06-12 | Handelsbanken Fonder increases stake in Alligo to just over 5 percent | FW |
| 06-08 | Espiria Sweden Small Cap rose 6.1 percent in May - Hansa Biopharma contributed positively | FW |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.18 | 4.91 | 5.46 | 3.45 | 3.1 | |||||
Return on Total Capital | 4.48 | 6.87 | 7.29 | 4.55 | 4.06 | |||||
Return On Equity % | 8.96 | 14.02 | 14.1 | 7.55 | 7.12 | |||||
Return on Common Equity | 8.97 | 14.04 | 13.99 | 7.47 | 6.99 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 41.28 | 40.73 | 41.7 | 40.88 | 41.09 | |||||
SG&A Margin | 19.55 | 18.83 | 19.27 | 20 | 20.5 | |||||
EBITDA Margin % | 7.69 | 9.05 | 9.8 | 7.5 | 7.18 | |||||
EBITA Margin % | 6.17 | 8.3 | 8.99 | 6.48 | 6.13 | |||||
EBIT Margin % | 4.95 | 7.23 | 7.99 | 5.44 | 5.01 | |||||
Income From Continuing Operations Margin % | 3.43 | 5.2 | 5.3 | 2.98 | 2.82 | |||||
Net Income Margin % | 5.05 | 43.9 | 5.24 | 2.93 | 2.73 | |||||
Net Avail. For Common Margin % | 3.41 | 5.19 | 5.24 | 2.93 | 2.73 | |||||
Normalized Net Income Margin | 2.78 | 4.16 | 4.17 | 2.4 | 2.29 | |||||
Levered Free Cash Flow Margin | 1.86 | 6.88 | 7.17 | 7.69 | 5.85 | |||||
Unlevered Free Cash Flow Margin | 2.15 | 7.27 | 7.99 | 8.72 | 6.78 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.03 | 1.09 | 1.09 | 1.01 | 0.99 | |||||
Fixed Assets Turnover | 5.81 | 6.12 | 5.54 | 5.02 | 4.97 | |||||
Receivables Turnover (Average Receivables) | 7.33 | 7.53 | 7.6 | 7.91 | 7.91 | |||||
Inventory Turnover (Average Inventory) | 2.76 | 2.65 | 2.37 | 2.3 | 2.27 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.66 | 1.91 | 2.02 | 2.03 | 2.03 | |||||
Quick Ratio | 0.58 | 0.77 | 0.83 | 0.9 | 0.87 | |||||
Operating Cash Flow to Current Liabilities | 0.34 | 0.21 | 0.48 | 0.42 | 0.36 | |||||
Days Sales Outstanding (Average Receivables) | 49.79 | 48.48 | 48.05 | 46.29 | 46.16 | |||||
Days Outstanding Inventory (Average Inventory) | 132.36 | 137.5 | 154.33 | 159.44 | 160.58 | |||||
Average Days Payable Outstanding | 77.78 | 68.46 | 68.75 | 69.65 | 71.89 | |||||
Cash Conversion Cycle (Average Days) | 104.37 | 117.52 | 133.63 | 136.08 | 134.85 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 74.19 | 80.93 | 83.04 | 95.13 | 95.6 | |||||
Total Debt / Total Capital | 42.59 | 44.73 | 45.37 | 48.75 | 48.88 | |||||
LT Debt/Equity | 60.76 | 70.61 | 72.11 | 83.09 | 83.14 | |||||
Long-Term Debt / Total Capital | 34.88 | 39.03 | 39.39 | 42.58 | 42.5 | |||||
Total Liabilities / Total Assets | 60.27 | 59.19 | 58.59 | 61.17 | 60.69 | |||||
EBIT / Interest Expense | 10.77 | 11.54 | 6.09 | 3.28 | 3.4 | |||||
EBITDA / Interest Expense | 26.56 | 19.92 | 10.42 | 7.21 | 7.71 | |||||
(EBITDA - Capex) / Interest Expense | 23.64 | 18.06 | 9.02 | 6.61 | 7.05 | |||||
Total Debt / EBITDA | 2.47 | 2.39 | 2.36 | 3.2 | 3.34 | |||||
Net Debt / EBITDA | 2.19 | 2.2 | 2.06 | 2.6 | 2.89 | |||||
Total Debt / (EBITDA - Capex) | 2.77 | 2.64 | 2.72 | 3.49 | 3.65 | |||||
Net Debt / (EBITDA - Capex) | 2.46 | 2.43 | 2.38 | 2.83 | 3.16 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 12.13 | 9.51 | 1.36 | -0.22 | 2.12 | |||||
Gross Profit, 1 Yr. Growth % | 21.23 | 8.87 | 3.77 | -2.17 | 2.64 | |||||
EBITDA, 1 Yr. Growth % | 31.92 | 40.02 | 10.46 | -23.28 | -0.87 | |||||
EBITA, 1 Yr. Growth % | 32.32 | 46.9 | 10.48 | -27.77 | -1.68 | |||||
EBIT, 1 Yr. Growth % | 39.53 | 59.74 | 12.8 | -31.68 | -4.01 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 46.23 | 65.29 | 3.33 | -43.86 | -3.58 | |||||
Net Income, 1 Yr. Growth % | 52.13 | 846.62 | -87.91 | -44.2 | -4.74 | |||||
Normalized Net Income, 1 Yr. Growth % | 47.77 | 63.58 | 2.46 | -42.23 | 0.34 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 29.9 | 65.43 | 2.64 | -43.96 | -4.75 | |||||
Accounts Receivable, 1 Yr. Growth % | 1.04 | 10.59 | -8.72 | 1.28 | 3.37 | |||||
Inventory, 1 Yr. Growth % | 5.39 | 22.58 | 3.21 | 5.24 | 0.4 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 0.62 | 6.13 | 17.41 | 3.83 | 2.53 | |||||
Total Assets, 1 Yr. Growth % | 11.1 | -3.63 | 5.06 | 10.08 | -0.17 | |||||
Tangible Book Value, 1 Yr. Growth % | 236.76 | -11.62 | 18.19 | -28.54 | -5.35 | |||||
Common Equity, 1 Yr. Growth % | 12.91 | -0.61 | 6.02 | 2.93 | 0.86 | |||||
Cash From Operations, 1 Yr. Growth % | -20.82 | -42.34 | 121.65 | -4.13 | -16.18 | |||||
Capital Expenditures, 1 Yr. Growth % | -11.63 | -0.92 | 59.26 | -45.93 | 0 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | - | 486.23 | 6.24 | 7.39 | -21.56 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | - | 405.97 | 11.98 | 9.31 | -20.06 | |||||
Dividend Per Share, 1 Yr. Growth % | -12.5 | 71.43 | 16.67 | -42.86 | 10 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | - | 10.52 | 5.35 | 0.57 | 0.94 | |||||
Gross Profit, 2 Yr. CAGR % | - | 14.14 | 6.29 | 0.75 | 0.2 | |||||
EBITDA, 2 Yr. CAGR % | - | 30.06 | 23.97 | -8.14 | -13.41 | |||||
EBITA, 2 Yr. CAGR % | - | 39.29 | 26.96 | -10.88 | -16.43 | |||||
EBIT, 2 Yr. CAGR % | - | 49.12 | 33.7 | -12.45 | -19.82 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 55.47 | 30.69 | -23.84 | -26.43 | |||||
Net Income, 2 Yr. CAGR % | - | 279.48 | 6.98 | -74.02 | -27.09 | |||||
Normalized Net Income, 2 Yr. CAGR % | - | 55.27 | 28.9 | -23.31 | -24.93 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | - | 46.59 | 30.31 | -24.15 | -26.94 | |||||
Accounts Receivable, 2 Yr. CAGR % | - | 5.71 | 0.47 | -3.85 | 2.32 | |||||
Inventory, 2 Yr. CAGR % | - | 13.66 | 12.48 | 4.22 | 2.79 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 3.34 | 11.63 | 10.41 | 3.18 | |||||
Total Assets, 2 Yr. CAGR % | - | 3.47 | 0.62 | 7.54 | 4.83 | |||||
Tangible Book Value, 2 Yr. CAGR % | - | 72.52 | 2.21 | -8.1 | -17.76 | |||||
Common Equity, 2 Yr. CAGR % | - | 5.93 | 2.65 | 4.46 | 1.89 | |||||
Cash From Operations, 2 Yr. CAGR % | - | -38.67 | 13.05 | 45.77 | -10.35 | |||||
Capital Expenditures, 2 Yr. CAGR % | - | -8.5 | 25.62 | -7.2 | -26.47 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 148.91 | 6.62 | -8.62 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 137.44 | 10.45 | -6.88 | |||||
Dividend Per Share, 2 Yr. CAGR % | - | 22.47 | 41.42 | -18.35 | -20.72 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | - | - | 7.38 | 3.46 | 1.08 | |||||
Gross Profit, 3 Yr. CAGR % | - | - | 10.58 | 3.39 | 1.38 | |||||
EBITDA, 3 Yr. CAGR % | - | - | 22.91 | 5.49 | -6.23 | |||||
EBITA, 3 Yr. CAGR % | - | - | 28.64 | 5.03 | -8.42 | |||||
EBIT, 3 Yr. CAGR % | - | - | 35.51 | 6.7 | -10.31 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 35.68 | -1.39 | -17.61 | |||||
Net Income, 3 Yr. CAGR % | - | - | 20.3 | -13.88 | -59.94 | |||||
Normalized Net Income, 3 Yr. CAGR % | - | - | 34.79 | -1.57 | -16.91 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | 30.17 | -1.64 | -18.17 | |||||
Accounts Receivable, 3 Yr. CAGR % | - | - | 0.66 | 0.74 | -1.5 | |||||
Inventory, 3 Yr. CAGR % | - | - | 10.06 | 10.01 | 2.93 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | 7.83 | 8.97 | 7.72 | |||||
Total Assets, 3 Yr. CAGR % | - | - | 4 | 3.68 | 4.91 | |||||
Tangible Book Value, 3 Yr. CAGR % | - | - | 52.09 | -9.29 | -7.19 | |||||
Common Equity, 3 Yr. CAGR % | - | - | 5.96 | 2.74 | 3.25 | |||||
Cash From Operations, 3 Yr. CAGR % | - | - | -5.88 | 7.01 | 21.22 | |||||
Capital Expenditures, 3 Yr. CAGR % | - | - | 10.06 | -5.15 | -4.86 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 87.85 | -4.03 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 83.13 | -1.09 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | - | 20.51 | 4.55 | -9.82 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | - | 4.75 | |||||
Gross Profit, 5 Yr. CAGR % | - | - | - | - | 6.3 | |||||
EBITDA, 5 Yr. CAGR % | - | - | - | - | 6.74 | |||||
EBITA, 5 Yr. CAGR % | - | - | - | - | 8.15 | |||||
EBIT, 5 Yr. CAGR % | - | - | - | - | 9.74 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 6.21 | |||||
Net Income, 5 Yr. CAGR % | - | - | - | - | -1.54 | |||||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 6.52 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | 3.32 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | - | 1.32 | |||||
Inventory, 5 Yr. CAGR % | - | - | - | - | 7.1 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 5.94 | |||||
Total Assets, 5 Yr. CAGR % | - | - | - | - | 4.33 | |||||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 18.93 | |||||
Common Equity, 5 Yr. CAGR % | - | - | - | - | 4.31 | |||||
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | -7.7 | |||||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | -6.33 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | - | - | - | 1.92 |
- Stock Market
- Stocks
- ALLIGO B Stock
- Financials Alligo AB
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















